Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy

Enrico Cortesi, Andrea Mancuso, Adolfo De Pasquale Ceratti, Nicolina Pizzardi, Giuliana D'Auria, Caterina Accettura, Patrizia Beccaglia, Daniela Bertelletti, Filippo De Marinis

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels

Original languageEnglish
Pages (from-to)459-468
Number of pages10
JournalThe oncologist
Volume9
Issue number4
DOIs
Publication statusPublished - 2004

Keywords

  • Anemia
  • Cancer
  • Epoetin alfa
  • Hemoglobin
  • Induction therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Fingerprint Dive into the research topics of 'Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy'. Together they form a unique fingerprint.

Cite this